Quinolone interactions with DNA and DNA gyrase.
Shen
L L
LL
Abbott Labs, Abbott Park, IL, USA.
D000890:Anti-Infective Agents / Q000378:metabolism* / Q000494:pharmacology; D001667:Binding, Competitive; D002021:Buffers; D002498:Centrifugation; D004250:DNA Topoisomerases, Type II / Q000378:metabolism*; D004278:DNA, Superhelical / Q000737:chemistry / Q000378:metabolism; D015195:Drug Design; D004926:Escherichia coli / Q000201:enzymology / Q000235:genetics; D008024:Ligands; D009643:Norfloxacin / Q000378:metabolism / Q000494:pharmacology; D009838:Oligodeoxyribonucleotides / Q000737:chemistry / Q000378:metabolism; D010957:Plasmids / Q000737:chemistry / Q000378:metabolism*; D013050:Spectrometry, Fluorescence; D013379:Substrate Specificity; D059005:Topoisomerase II Inhibitors; D014462:Ultrafiltration
D000890:Anti-Infective Agents; D002021:Buffers; D004278:DNA, Superhelical; D008024:Ligands; D009838:Oligodeoxyribonucleotides; D059005:Topoisomerase II Inhibitors; D004250:DNA Topoisomerases, Type II; D009643:Norfloxacin